Marshall Wace LLP Purchases 19,635 Shares of Surmodics, Inc. (NASDAQ:SRDX)

Marshall Wace LLP increased its position in Surmodics, Inc. (NASDAQ:SRDX) by 231.0% in the 4th quarter, Holdings Channel reports. The firm owned 28,135 shares of the company’s stock after buying an additional 19,635 shares during the quarter. Marshall Wace LLP’s holdings in Surmodics were worth $1,114,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Modus Advisors LLC bought a new position in Surmodics in the fourth quarter worth $40,000. R Squared Ltd bought a new position in Surmodics in the fourth quarter worth $55,000. Legal & General Group Plc lifted its position in Surmodics by 34.2% in the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after purchasing an additional 880 shares during the period. Polymer Capital Management US LLC bought a new position in Surmodics in the fourth quarter worth $255,000. Finally, SG Americas Securities LLC lifted its position in Surmodics by 22.1% in the fourth quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock worth $275,000 after purchasing an additional 1,255 shares during the period. 96.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Lake Street Capital upgraded Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Friday, March 7th. StockNews.com assumed coverage on Surmodics in a research note on Monday, February 3rd. They set a “hold” rating for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Surmodics has an average rating of “Hold” and a consensus price target of $50.00.

Surmodics Stock Performance

Shares of NASDAQ:SRDX opened at $30.93 on Wednesday. Surmodics, Inc. has a twelve month low of $25.17 and a twelve month high of $42.44. The firm has a market cap of $442.18 million, a PE ratio of -30.62 and a beta of 1.30. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. The business has a fifty day moving average of $29.87 and a 200-day moving average of $35.11.

Surmodics (NASDAQ:SRDX) last announced its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. On average, equities research analysts predict that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).